REVIEW

Multiple system atrophy: genetic risks and alpha-synuclein mutations [version 1; peer review: 2 approved]

Heather T Whittaker¹, Yichen Qui², Conceição Bettencourt^{1,2}, Henry Houlden^{1,3,4}

¹Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

²Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK

³MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, UK

⁴Neurogenetics Laboratory, The National Hospital for Neurology and Neurosurgery, London, UK

V1 First published: 30 Nov 2017, 6(F1000 Faculty Rev):2072
<https://doi.org/10.12688/f1000research.12193.1>

Latest published: 30 Nov 2017, 6(F1000 Faculty Rev):2072
<https://doi.org/10.12688/f1000research.12193.1>

Abstract

Multiple system atrophy (MSA) is one of the few neurodegenerative disorders where we have a significant understanding of the clinical and pathological manifestations but where the aetiology remains almost completely unknown. Research to overcome this hurdle is gaining momentum through international research collaboration and a series of genetic and molecular discoveries in the last few years, which have advanced our knowledge of this rare synucleinopathy. In MSA, the discovery of α -synuclein pathology and glial cytoplasmic inclusions remain the most significant findings. Families with certain types of α -synuclein mutations develop diseases that mimic MSA, and the spectrum of clinical and pathological features in these families suggests a spectrum of severity, from late-onset Parkinson's disease to MSA. Nonetheless, controversies persist, such as the role of common α -synuclein variants in MSA and whether this disorder shares a common mechanism of spreading pathology with other protein misfolding neurodegenerative diseases. Here, we review these issues, specifically focusing on α -synuclein mutations.

Keywords

multiple system atrophy, MSA, neurodegenerative disorders, α -synuclein

Open Peer Review

Approval Status

	1	2
version 1
30 Nov 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Mathias Toft**, Oslo University Hospital, Oslo, Norway
2. **Dean Pountney**, Griffith University, Queensland, Australia

Any comments on the article can be found at the end of the article.

Corresponding author: Henry Houlden (h.houlden@ucl.ac.uk)

Author roles: Whittaker HT: Writing – Original Draft Preparation; Qui Y: Writing – Original Draft Preparation; Bettencourt C: Writing – Original Draft Preparation; Houlden H: Conceptualization, Project Administration, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: We are grateful to the MSA Trust, the MSA Coalition (HH-MSA Coalition), the Medical Research Council (MRC UK) (HH-MRC), the Wellcome Trust (HH-WT)—equipment and the Synaptopathies Strategic Award (104033)—and the EU FP7/2007-2013 under grant agreement 2012-305121 (NEUROMICS), the MDA USA, Muscular Dystrophy UK, the Rosetrees Trust, Ataxia UK, and the Brain Research Trust. We are also supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Whittaker HT *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Whittaker HT, Qui Y, Bettencourt C and Houlden H. **Multiple system atrophy: genetic risks and alpha-synuclein mutations [version 1; peer review: 2 approved]** F1000Research 2017, 6(F1000 Faculty Rev):2072 <https://doi.org/10.12688/f1000research.12193.1>

First published: 30 Nov 2017, 6(F1000 Faculty Rev):2072 <https://doi.org/10.12688/f1000research.12193.1>

Introduction

Multiple system atrophy (MSA) is a neurodegenerative movement disorder affecting around 1 in 20,000 people^{1,2}. It occurs sporadically, usually presenting between the age of 35 and 65 years with a variable combination of parkinsonian, cerebellar, and autonomic features and rapidly progressing for 9 years on average^{3–6}. According to the presenting clinical features and predominant manifestations, MSA is usually categorised as MSA-C or MSA-P, there can be mixed signs, and some patients present with autonomic features. Familial MSA has been reported but in only a handful of cases worldwide. Research toward potential treatments for MSA, as with many rare diseases, has been limited, resulting in a paucity of knowledge regarding its underlying causes. Initial clues came from studying α -synuclein (SNCA) and the hallmark histopathology in the brains of patients with MSA: glial cytoplasmic inclusions (GCIs) that reside predominantly in oligodendrocytes, the post mortem identification of which is required for a definitive diagnosis. Besides MSA, the only conditions that have GCIs in the brain are certain families with SNCA mutations. Three groups found that the GCIs contain abnormal forms of SNCA protein^{7–12}, the same protein that accumulates in Parkinson's disease (PD) and dementia with Lewy bodies¹². These studies were motivated by a link between point mutations in the *SNCA* gene and heritable forms of PD^{13,14}. The similarities between MSA and PD have proven more complicated to disentangle, as SNCA mutations in some families clinically and pathologically resemble MSA and others even have features of frontal dementia with severe pathology¹⁵.

It has been nearly two decades since MSA was characterised as a synucleinopathy, and apart from the PD-MSA overlap identified in SNCA families, researchers have not been able to further understand the aetiology of MSA or alter or halt the disease process. This brief review will set out the progress that has been made in recent years toward understanding the pathomechanisms of SNCA aggregation and toxicity in relation to MSA, particularly the emerging hypotheses of aetiology based on genetic studies. As clinical trials targeting SNCA proceed in PD and MSA, there is increasing urgency to better understand its relevant cellular interactions in parallel with the development of sensitive biomarkers capable of diagnosing patients at an earlier disease stage.

The role of α -synuclein in multiple system atrophy

Despite the key involvement of abnormal SNCA processing, misfolding, and aggregation in synucleinopathies, the normal function of the protein is not fully understood. It is a peripheral membrane protein, localized at nerve terminals where it is thought to play a role in the release of neurotransmitters, and recently has been reported to enhance transient synaptic vesicle fusion^{16,17} and possibly disrupt the support and maintenance of neurons provided by oligodendrocytes. In MSA, SNCA is deposited widely, but there are more severely affected regions such as the basal ganglia, cerebellum, pons, inferior olivary nuclei, and spinal cord^{18,19}. Not only is SNCA deposition clearly distinguishable between MSA and PD cases but MSA-like pathology underlies both cerebellar (MSA-C) and parkinsonian (MSA-P)

manifestations. There is also minimal change MSA pathology in some cases that have a longer disease duration. How this single protein can apparently be the culprit in these different disease phenotypes, with such varied localization in different cell types and brain regions, is an unresolved question.

One compelling explanation for the clinicopathological diversity in the synucleinopathies is that distinct strains of SNCA are responsible for generating heterogeneity²⁰. These conformational variants include different oligomer combinations, fibrils and ribbons, although their relative contribution to the anatomical distribution and deposition of SNCA in MSA and other synucleinopathies and the formation of GCIs in MSA has yet to be determined. Furthermore, it has been posited that the specific structure of SNCA derived from inclusions in the brains of patients with MSA is especially toxic, capable of propagating to adjacent cells and inducing neurodegeneration when injected into transgenic mice, akin to the permissive templating of prion protein and even prompting reclassification of MSA as a prion disease^{21,22}. However, it remains to be shown conclusively that oligodendroglial MSA-type pathology is provoked by seeded aggregation of SNCA.

The pathomechanisms of MSA are being steadily elucidated as studies examine the molecular interactions of SNCA with other proteins in MSA. A recent study²³ has reported that SNCA engages with proteins that regulate autophagy in the MSA brain, implicating cellular degradation as central to the pathogenesis of MSA and potentially unifying it with other neurodegenerative diseases for the purpose of therapeutic intervention of these pathways^{23,24}. Additionally, there is an emerging conviction that SNCA induces deficits in myelination²⁵ and there is a possible role for inflammatory/apoptotic mechanisms.

Mutations and copy number variation in α -synuclein

The initial genome-wide association study (GWAS) in PD yielded significant association at the *SNCA* and microtubule-associated protein tau (*MAPT*) genes²⁶. Common variation in the gene encoding SNCA was first identified as a risk factor for MSA in 2009²⁷, but the association of variants across *SNCA* in different populations was not replicated in later studies^{28–32} and was thought to be due to a mixed control population used in the initial studies. The first GWAS to be conducted in MSA yielded negative results around the *SNCA* locus²⁸. As mentioned earlier, several SNCA point mutations^{14,33–39} and *SNCA* gene duplications⁴⁰, triplications^{41,42}, and double duplications⁴³ have been associated with familial forms of PD (Figure 1 and Table 1 and Table 2). Some of these families have manifestations of both PD and MSA and have clinical signs or neuropathological features or both^{44,45}. In particular, the A53T, A53E, and G51D mutations and *SNCA* gene triplications are associated with a more aggressive MSA-like clinical and pathological phenotype⁴⁵ (See Table 1 and Table 2 for details of the clinical and neuropathological features of SNCA mutations). Exactly why the codon 51 and 53 mutations in the *SNCA* gene lead to an MSA-like clinical and pathological phenotype is not known, but this is likely to be associated with the importance of this defined region and toxic gain of function of these protein changes (Figure 1)⁴⁶.

Figure 1. Structural features of the alpha-synuclein monomer. A structure of the full-length, membrane-bound form of alpha-synuclein (SNCA) protein reveals a conformation in which the N-terminal two-thirds of the protein forms a broken, amphipathic alpha-helix. This structured portion of the protein is responsible for membrane binding, and residues at the very N-terminus are essential for this process. In the nuclear magnetic resonance structure of SNCA, the negatively charged C-terminal tail remains flexible and disordered (based on Yu *et al.*⁴⁶). The positions of point mutations associated with Parkinson's disease are indicated with arrows and in pink. All mutations are heterozygous, except for p.A53V, which is homozygous.

From a clinical perspective, if there is any hint of a family history in patients with MSA, then the *SNCA* gene should be sequenced by using traditional Sanger⁴⁷, gene panel, or exome sequencing and analysed for copy number changes⁴⁸.

Other genetic risk factors for multiple system atrophy

A number of PD risk factors have not been replicated in MSA^{4,6,48–61}, but other disorders such as spinocerebellar ataxia type 17 and progressive supranuclear palsy^{62–64} can mimic MSA in the early stages and should be included in clinical and genetic testing. In a statistical analysis of 5,302 patients with PD and 4,161 controls from 15 sites, Elbaz and colleagues found no evidence for an interactive effect between the H1 haplotype in the *MAPT* gene and single-nucleotide polymorphisms in the *SNCA* gene on disease⁶⁵. Variation in each gene was associated with PD risk, indicating independent effects. In MSA, the H1 haplotype has been associated with MSA⁶⁶ and the *MAPT* gene was also implicated in the MSA GWAS²⁸. Familial inheritance of MSA is rare but has been observed. These families often have atypical clinical features, and the genetic analysis led to the discovery of mutations in the *COQ2* gene, which plays a role in synthesising the mitochondrial electron transporter and antioxidant coenzyme Q₁₀. These mutations were posited to impair the activity of the mitochondrial respiratory chain and increase oxidative stress, implicating *COQ2* variants as a risk factor for sporadic MSA⁵⁸.

Though initially promising, these findings have not been consistently replicated in various populations, refuting *COQ2* polymorphisms as common MSA risk factors⁵⁸. Nonetheless, this has turned attention, and emerging hypotheses centre on mitochondrial dysfunction as a central component of the pathophysiological cascade in MSA⁶⁷.

The first GWAS in MSA was carried out by Sailer and colleagues and was extremely important but challenging given the rarity of MSA²⁸. At just under 1,000 MSA cases, the analysis was still statistically under-powered²⁸. Studies that are more highly powered are needed to follow up on the importance of the three genes identified that were flagged for being associated: *FBXO47*, *ELOVL7*, and *MAPT*²⁸. It will be important to follow this GWAS up with greater numbers of MSA cases, analyse age at onset association^{68–70}, and employ advanced transcriptome sequencing in MSA patient brain tissue to assess the associated genes and other genes thought to be involved in MSA, such as immune-responsive and iron metabolism genes^{71,72}.

Clinical genetic testing and translation

Accurate and early diagnosis of MSA continues to be an important research objective as the heterogeneous features of PD and other atypical parkinsonism syndromes can mimic MSA. One retrospective clinicopathological study revealed that 38% of patients were misdiagnosed with MSA on the basis of expert interpretation

Table 1. Clinical features of families with alpha-synuclein (SNCA) mutations.

SNCA protein change	p.Ala30Pro ¹	p.Glu46Lys ²	p.His50Gln ³	p.Gly51Asp ^{4,5}	p.Ala53Thr ⁶	p.Ala53Glu ⁷	p.Ala53Val ⁸	Duplication ⁹	Triplication ¹⁰	Double duplication ¹¹
SNCA: 5' start - ATG start -	177G>C c.88G>C	225G>A c.136G>A	239T>G c.150T>G12	241G>A c.152 G>A	246G>A c.157G>A	247C>A c.158C>A	247C>T c.158C>T	Whole gene copy number	Whole gene copy number	Whole gene copy number
Zygosity	Heterozygous	Heterozygous	Heterozygous	Heterozygous	Heterozygous	Heterozygous	Homozygous/heterozygous	Gene duplication on one allele	Gene triplication on one allele	Gene duplication on both alleles
Clinical phenotype	Classic PD	Dementia with Lewy bodies phenotype	Classic PD	Severe PD with some patients with MSA features	Severe PD with some patients with MSA features	Severe PD with some patients with MSA features	Homozygous = PD Heterozygous = cognitive decline or psychosis	Usually classic PD, some with severe cognitive and frontal dementia ¹³	Severe PD with some patients with MSA features	Severe PD
Family	German ¹⁴	Spanish Basque Country ¹⁵	English ¹⁶	British ⁴ , French ¹⁷ and Japanese ¹⁸	Large Sicilian (Contursi) kindred ¹⁶ and Greek ¹⁹ , Swedish ²⁰ , Korean ²¹	Finnish ²²	Japanese ²³	French ²⁴ , Italian ²⁵ , Japanese ^{26,27} , Korean ²⁸ , Swedish ²⁹ , UK, Welsh ¹³	Spellman-Muenter (Iowa) kindred ³⁰ , Swedish ⁹	Pakistani ³¹
Estimated penetrance/risk	71.4%	30%	30% Heterozygous ExAc = 4/121,306	100%	85%	100%	Homozygous 100% Heterozygous on ExAc = 1/121,304	44% ²⁷	100%	100%
Mean age of onset, years	60	50–65	71	44 (as early as 19) ⁵	48	43	59	50	40	31
Clinical symptoms	Progressive parkinsonism, walking difficulties, no other non-motor symptoms except cognitive decline (50% of patients)	Resting tremor, bradykinesia, postural instability, severe immobility, dementia, and visual hallucinations	Resting hand tremor, benign course	Resting tremor, dystonia, cognitive/frontal decline, anxiety, depression, visual hallucination, and autonomic disturbances ⁵	Moderate tremor, rigidity, bradykinesia, postural instability, severe dementia, depression, and autonomic disturbance ³²	Bradykinesia, resting tremor, rigidity, insomnia, spasticity, myoclonic jerks, anxiety, and panic disorders	Bradykinesia, resting tremor, rigidity, mild cognitive decline, visual hallucination, sleep disorder, delusions, and paranoia	Bradykinesia, resting tremor, rigidity, mild asymmetric onset. Some have epilepsy, depression, and frontal dementia.	Severe early onset parkinsonism, resting tremor, bradykinesia, mild resting rigidity, and symptoms of MSA	Severe bilateral bradykinesia, rigidity, mild resting tremor, severe depression, and postpartum psychosis
Sustained response to levodopa	Transient marked, developed hallucinations	Mild to moderate, developed hallucinations and conscious fluctuation	Moderate	Transient marked, developed choreiform movements	Marked	Marked, developed dyskinesia ³³	Marked	Mild to moderate, developed motor fluctuation and dyskinesia	Marked	N/A

ExAC, <http://exac.broadinstitute.org>; MSA, multiple system atrophy; N/A, no data available; PD, Parkinson's disease; SNCA, alpha-synuclein gene.

Table 2. Neuropathological features of families with alpha-synuclein (SNCA) mutations.

SNCA protein change	p.Ala30Pro ¹	p.Glu46Lys ²	p.His50Gln ³	p.Gly51Asp ^{4,5}	p.Ala53Thr ^{6,34}	p.Ala53Glu ⁷	Duplication ³⁵	Triplication ¹⁰
Neuropathology summary	Widespread synuclein neuropathology and LBs	Widespread synuclein and ubiquitin neuropathology and LBs	Widespread synuclein neuropathology and LBs	Widespread synuclein neuropathology, LBs, and GCIs	Widespread synuclein neuropathology, LBs, and GCIs	Widespread synuclein neuropathology, LBs, and GCIs	Widespread synuclein neuropathology, LBs, and some GCIs	Widespread synuclein neuropathology, LBs, and GCIs
LBs	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cortical neuronal loss	Widespread	Widespread	Not identified	Widespread, moderate to severe, anterior temporal, piriform, and insular cortices ⁴	Widespread, moderate to severe, mid-frontal cortex, superior temporal cortex, and inferior parietal cortex	Widespread and severe	Not identified	Widespread
Hippocampal neuronal loss	CA1/2/3	Not identified	Not identified	Severe in CA2/3 ⁴	Severe in CA1, moderate in CA2/3 ³⁴	Mild in CA1/2/3	CA2/3 region	CA2/3 region
Brain stem neuronal loss	Substantia nigra, locus coeruleus, and dorsal nuclei of the vagus	Substantia nigra, locus coeruleus, and dorsal nuclei of the vagus	Substantia nigra	Substantia nigra, locus coeruleus, and dorsal motor nuclei of vagus	Substantia nigra and locus coeruleus	Substantia nigra	Substantia nigra, locus coeruleus, and dorsal motor nuclei of vagus	Substantia nigra and locus coeruleus
Neuronal α -synuclein pathology	Globular, spherical, reniform, widespread throughout cortex and brainstem	Concentric, nonconcentric, granular	PD-type (Braak stage 6)	Annular, crescentic, globular, diffuse, NFT-like, Widespread cortical	Wide spread cortex and brain stem, LBs	Annular, annular, LB-like inclusions, mild in brainstem	PD-type (Braak stage 6), widespread from brainstem and neocortex	Widespread in cortex, few in brainstem
Glial α -synuclein pathology	No	No	No	GCI-like	GCI-like	Granular GCI	GCI-like	Atypical LBs, GCIs
Phosphorylated tau Braak and Braak stage	II	Not identified	III	IIa	I	N/A	I	N/A
A β deposition	Thal phase 1 ³⁶	Neocortical	Neocortical	N/A	N/A	N/A	Sparse neocortical	N/A

There has been no neuropathology on the p.Ala53Val mutation, and the double duplication has no brain donation. GCI, glial cytoplasmic inclusions; LB, Lewy body; N/A, no data available; NFT, neurofibrillary tangle; PD, Parkinson's disease.

of their symptomatic presentation^{73–75}. Genetic analysis will be important to identify the rare MSA cases with *SNCA* mutations and to help differentiate MSA from similar disorders such as spinocerebellar ataxia type 17^{62,64}. Thus, biomarkers that are more sensitive are imperative to improve diagnosis and enlist individuals with the appropriate disease in clinical trials. This will be imperative in the development of effective treatments for the MSA patient population. Both α -synuclein and CoQ₁₀ are being pursued as potential therapeutic targets, and international collaborative study groups are promoting this work with CoQ₁₀ supplementation, the preparation of α -synuclein antisense oligonucleotide, and immunisation trials to be conducted in PD and MSA patients by either intravenous or intrathecal routes.

Until disease-modifying treatments become available, symptom management will remain the mainstay of care for patients with MSA. Patient support organisations such as the MSA Trust (www.msatrust.org.uk/) and the MSA coalition (<https://www.multiplesystematrophy.org/>) and their clinical nurse specialists are essential in providing support and advice on patient care in this rare disorder. The established drugs for controlling parkinsonism, such as L-dopa, can be effective in the early stages of MSA but often worsen the symptoms due to hypotension later in the disease. A rational treatment, based on the pathophysiology of MSA and

perhaps repurposed from PD trials, needs to be developed to offer patients with MSA hope for this devastating disorder.

Competing interests

The authors declare that they have no competing interests.

Grant information

We are grateful to the MSA Trust, the MSA Coalition, the Medical Research Council (MRC UK), the Wellcome Trust—equipment and the Synaptopathies Strategic Award (104033)—and the EU FP7/2007-2013 under grant agreement 2012-305121 (NEUROMICS), the MDA USA, Muscular Dystrophy UK, the Rosetrees Trust, Ataxia UK, and the Brain Research Trust. We are also supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

The authors would like to thank the patients and their families for their essential help with this work.

References

- Schrag A, Ben-Shlomo Y, Quinn NP: **Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.** *Lancet*. 1999; **354**(9192): 1771–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tison F, Yekhelef F, Chrysostome V, *et al.*: **Prevalence of multiple system atrophy.** *Lancet*. 2000; **355**(9202): 495–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ahmed Z, Asi YT, Sailer A, *et al.*: **The neuropathology, pathophysiology and genetics of multiple system atrophy.** *Neuropathol Appl Neurobiol*. 2012; **38**(1): 4–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Federoff M, Schottlaender LV, Houlden H, *et al.*: **Multiple system atrophy: the application of genetics in understanding etiology.** *Clin Auton Res*. 2015; **25**(1): 19–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Federoff M, Price TR, Sailer A, *et al.*: **Genome-wide estimate of the heritability of Multiple System Atrophy.** *Parkinsonism Relat Disord*. 2016; **22**: 35–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kara E, Xiromerisiou G, Spanaki C, *et al.*: **Assessment of Parkinson's disease risk loci in Greece.** *Neurobiol Aging*. 2014; **35**(2): 442.e9–442.e16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lantos PL, Papp MI: **Cellular pathology of multiple system atrophy: a review.** *J Neurol Neurosurg Psychiatr*. 1994; **57**(2): 129–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mezey E, Dehejia A, Harta G, *et al.*: **Alpha synuclein in neurodegenerative disorders: murderer or accomplice?** *Nat Med*. 1998; **4**(7): 755–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Papp MI, Kahn JE, Lantos PL: **Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).** *J Neurol Sci*. 1989; **94**(1–3): 79–100.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Papp MI, Lantos PL: **Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy.** *J Neurol Sci*. 1992; **107**(2): 172–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Papp MI, Lantos PL: **The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology.** *Brain*. 1994; **117**(Pt 2): 235–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Spillantini MG, Goedert M: **The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.** *Ann N Y Acad Sci*. 2000; **920**: 16–27.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Polymeropoulos MH: **Genetics of Parkinson's disease.** *Ann N Y Acad Sci*. 2000; **920**: 28–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Polymeropoulos MH, Lavedan C, Leroy E, *et al.*: **Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.** *Science*. 1997; **276**(5321): 2045–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kara E, Kiely AP, Proukakis C, *et al.*: **A 6.4 Mb duplication of the α -synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations.** *JAMA Neurol*. 2014; **71**(9): 1162–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Logan T, Bendor J, Toupin C, *et al.*: **α -Synuclein promotes dilation of the exocytotic fusion pore.** *Nat Neurosci*. 2017; **20**(5): 681–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
- Bendor JT, Logan TP, Edwards RH: **The function of α -synuclein.** *Neuron*. 2013; **79**(6): 1044–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Doppler K, Weis J, Karl K, *et al.*: **Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy.** *Mov Disord*. 2015; **30**(12): 1688–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
- Zange L, Noack C, Hahn K, *et al.*: **Phosphorylated α -synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy.** *Brain*. 2015; **138**(Pt 8): 2310–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
- Peelaerts W, Bousset L, van der Perren A, *et al.*: **α -Synuclein strains cause distinct synucleinopathies after local and systemic administration.** *Nature*. 2015; **522**(7556): 340–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**

21. **F** Prusiner SB, Woerman AL, Mordes DA, *et al.*: Evidence for α -synuclein prions causing multiple system atrophy in humans with parkinsonism. *Proc Natl Acad Sci U S A*. 2015; **112**(38): E5308–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
22. **F** Woerman AL, Watts JC, Aoyagi A, *et al.*: α -Synuclein: Multiple System Atrophy Prions. *Cold Spring Harb Perspect Med*. 2017; pii: a024588.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
23. **F** Miki Y, Tanji K, Mori F, *et al.*: AMBRA1, a novel α -synuclein-binding protein, is implicated in the pathogenesis of multiple system atrophy. *Brain Pathol*. 2016.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
24. Ghiso JA, Holton J, Miravalle L, *et al.*: Systemic amyloid deposits in familial British dementia. *J Biol Chem*. 2001; **276**(47): 43909–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. **F** Ettle B, Kerman BE, Valera E, *et al.*: α -Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy. *Acta Neuropathol*. 2016; **132**(1): 59–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
26. **F** Simón-Sánchez J, Schulte C, Bras JM, *et al.*: Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nat Genet*. 2009; **41**(12): 1308–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
27. Scholz SW, Houlden H, Schulte C, *et al.*: SNCA variants are associated with increased risk for multiple system atrophy. *Ann Neurol*. 2009; **65**(5): 610–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Sailer A, Scholz SW, Nalls MA, *et al.*: A genome-wide association study in multiple system atrophy. *Neurology*. 2016; **87**(15): 1591–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Conedera S, Apaydin H, Li Y, *et al.*: FBXO7 mutations in Parkinson's disease and multiple system atrophy. *Neurobiol Aging*. 2016; **40**: 192.e1–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Chen Y, Wei Q, Ou R, *et al.*: Genetic Variants of SNCA Are Associated with Susceptibility to Parkinson's Disease but Not Amyotrophic Lateral Sclerosis or Multiple System Atrophy in a Chinese Population. *PLoS One*. 2015; **10**(7): e0133776.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Sun Z, Xiang X, Tang B, *et al.*: SNP rs11931074 of the SNCA gene may not be associated with multiple system atrophy in Chinese population. *Int J Neurosci*. 2015; **125**(8): 612–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Al-Chalabi A, Dürr A, Wood NW, *et al.*: Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. *PLoS One*. 2009; **4**(9): e7114.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Krüger R, Kuhn W, Müller T, *et al.*: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. *Nat Genet*. 1998; **18**(2): 106–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Proukakis C, Dudzik CG, Brier T, *et al.*: A novel α -synuclein missense mutation in Parkinson disease. *Neurology*. 2013; **80**(11): 1062–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Kiely AP, Asi YT, Kara E, *et al.*: α -Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? *Acta Neuropathol*. 2013; **125**(5): 753–69.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. **F** Zarranz JJ, Alegre J, Gómez-Esteban JC, *et al.*: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. *Ann Neurol*. 2004; **55**(2): 164–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. Lesage S, Anheim M, Letournel F, *et al.*: G51D α -synuclein mutation causes a novel parkinsonian-pyramidal syndrome. *Ann Neurol*. 2013; **73**(4): 459–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Pasanen P, Myllykangas L, Siitonen M, *et al.*: Novel α -synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. *Neurobiol Aging*. 2014; **35**(9): 2180.e1–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. **F** Yoshino H, Hirano M, Stoessl AJ, *et al.*: Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. *Neurobiol Aging*. 2017; **57**: 248.e7–248.e12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. Ibáñez P, Bonnet AM, Débarges B, *et al.*: Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. *Lancet*. 2004; **364**(9440): 1169–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Johnson J, Hague SM, Hanson M, *et al.*: SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. *Neurology*. 2004; **63**(3): 554–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. **F** Singleton AB, Farrer M, Johnson J, *et al.*: alpha-Synuclein locus triplication causes Parkinson's disease. *Science*. 2003; **302**(5646): 841.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
43. Kojovic M, Sheerin UM, Rubio-Agusti I, *et al.*: Young-onset parkinsonism due to homozygous duplication of α -synuclein in a consanguineous family. *Mov Disord*. 2012; **27**(14): 1827–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. **F** Fanciulli A, Wenning GK: Multiple-system atrophy. *N Engl J Med*. 2015; **372**(3): 249–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
45. Kiely AP, Ling H, Asi YT, *et al.*: Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. *Mol Neurodegener*. 2015; **10**: 41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. **F** Yu H, Han W, Ma W, *et al.*: Transient β -hairpin formation in α -synuclein monomer revealed by coarse-grained molecular dynamics simulation. *J Chem Phys*. 2015; **143**(24): 243142.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
47. Houlden H, King RH, Hashemi-Nejad A, *et al.*: A novel TRK A (NTRK1) mutation associated with hereditary sensory and autonomic neuropathy type V. *Ann Neurol*. 2001; **49**(4): 521–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Singleton AB, Hardy J, Traynor BJ, *et al.*: Towards a complete resolution of the genetic architecture of disease. *Trends Genet*. 2010; **26**(10): 438–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Paisán-Ruiz C, Guevara R, Federoff M, *et al.*: Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. *Mov Disord*. 2010; **25**(12): 1791–800.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Tucci A, Nalls MA, Houlden H, *et al.*: Genetic variability at the PARK16 locus. *Eur J Hum Genet*. 2010; **18**(12): 1356–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Brooks JA, Houlden H, Melchers A, *et al.*: Mutational analysis of parkin and PINK1 in multiple system atrophy. *Neurobiol Aging*. 2011; **32**(3): 548.e5–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Houlden H, Singleton AB: The genetics and neuropathology of Parkinson's disease. *Acta Neuropathol*. 2012; **124**(3): 325–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Kara E, Ling H, Pittman AM, *et al.*: The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. *Neurobiol Aging*. 2012; **33**(9): 2231.e7–2231.e14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Paudel R, Hardy J, Revesz T, *et al.*: Review: genetics and neuropathology of primary pure dystonia. *Neuropathol Appl Neurobiol*. 2012; **38**(6): 520–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Duran R, Mencacci NE, Angeli AV, *et al.*: The glucocerebrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. *Mov Disord*. 2013; **28**(2): 232–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Kara E, Hardy J, Houlden H: The pallidopyramidal syndromes: nosology, aetiology and pathogenesis. *Curr Opin Neurol*. 2013; **26**(4): 381–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
57. Proukakis C, Houlden H, Schapira AH: Somatic alpha-synuclein mutations in Parkinson's disease: hypothesis and preliminary data. *Mov Disord*. 2013; **28**(6): 705–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Schottlaender LV, Houlden H: Multiple-System Atrophy (MSA) Brain Bank Collaboration: Mutant COQ2 in multiple-system atrophy. *N Engl J Med*. 2014; **371**(1): 81.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Schottlaender LV, Polke JM, Ling H, *et al.*: Analysis of C9orf72 repeat expansions in a large series of clinically and pathologically diagnosed cases with atypical parkinsonism. *Neurobiol Aging*. 2015; **36**(2): 1221.e1–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
60. Segarane B, Li A, Paudel R, *et al.*: Glucocerebrosidase mutations in 108 neuropathologically confirmed cases of multiple system atrophy. *Neurology*. 2009; **72**(13): 1185–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Scholz SW, Majounie E, Revesz T, *et al.*: Multiple system atrophy is not caused by C9orf72 hexanucleotide repeat expansions. *Neurobiol Aging*. 2015; **36**(2): 1223.e1–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
62. Kim HJ, Jeon BS, Shin J, *et al.*: Should genetic testing for SCAs be included in the diagnostic workup for MSA? *Neurology*. 2014; **83**(19): 1733–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Kim JY, Kim SY, Kim JM, *et al.*: Spinocerebellar ataxia type 17 mutation as a causative and susceptibility gene in parkinsonism. *Neurology*. 2009; **72**(16): 1385–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Lin IS, Wu RM, Lee-Chen GJ, *et al.*: The SCA17 phenotype can include features of MSA-C, PSP and cognitive impairment. *Parkinsonism Relat Disord*. 2007; **13**(4): 246–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Elbaz A, Ross OA, Ioannidis JP, *et al.*: Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. *Ann Neurol*. 2011; **69**(5): 778–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

66. **F** Labbé C, Heckman MG, Lorenzo-Betancor O, *et al.*: **MAPT haplotype diversity in multiple system atrophy**. *Parkinsonism Relat Disord*. 2016; **30**: 40–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
67. Schottlaender LV, Bettencourt C, Kiely AP, *et al.*: **Coenzyme Q10 Levels Are Decreased in the Cerebellum of Multiple-System Atrophy Patients**. *PLoS One*. 2016; **11**(2): e0149557.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
68. Houlden H, Baker M, Adamson J, *et al.*: **Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia**. *Ann Neurol*. 1999; **46**(2): 243–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Houlden H, Rizzu P, Stevens M, *et al.*: **Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations**. *Neurosci Lett*. 1999; **260**(3): 193–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Talbot C, Houlden H, Craddock N, *et al.*: **Polymorphism in AACT gene may lower age of onset of Alzheimer's disease**. *Neuroreport*. 1996; **7**(2): 534–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Chen BJ, Mills JD, Takenaka K, *et al.*: **Characterization of circular RNAs landscape in multiple system atrophy brain**. *J Neurochem*. 2016; **139**(3): 485–96.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Mills JD, Ward M, Kim WS, *et al.*: **Strand-specific RNA-sequencing analysis of multiple system atrophy brain transcriptome**. *Neuroscience*. 2016; **322**: 234–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. **F** Koga S, Aoki N, Uitti RJ, *et al.*: **When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients**. *Neurology*. 2015; **85**(5): 404–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
74. **F** Aoki N, Boyer PJ, Lund C, *et al.*: **Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with α -synuclein**. *Acta Neuropathol*. 2015; **130**(1): 93–105.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
75. Joutsa J, Gardberg M, Röttä M, *et al.*: **Diagnostic accuracy of parkinsonism syndromes by general neurologists**. *Parkinsonism Relat Disord*. 2014; **20**(8): 840–4.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Dean Pountney**

School of Medical Science, Griffith University, Queensland, Australia

Competing Interests: No competing interests were disclosed.

2. **Mathias Toft**

Department of Neurology, Oslo University Hospital, Oslo, Norway

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research